{'52WeekChange': 0.04000008,
 'SandP52WeekChange': 0.0644362,
 'address1': '75/76 Wimpole Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.95,
 'askSize': 900,
 'averageDailyVolume10Day': 228412,
 'averageVolume': 392793,
 'averageVolume10days': 228412,
 'beta': 1.632144,
 'beta3Year': None,
 'bid': 1.95,
 'bidSize': 3000,
 'bookValue': 0.063,
 'category': None,
 'circulatingSupply': None,
 'city': 'London',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2,
 'dayLow': 1.94,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.202,
 'enterpriseToRevenue': None,
 'enterpriseValue': 48199284,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 2.1513143,
 'fiftyTwoWeekHigh': 3.35,
 'fiftyTwoWeekLow': 0.87,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 13751689,
 'forwardEps': -0.01,
 'forwardPE': -195.00002,
 'fromCurrency': None,
 'fullTimeEmployees': 10,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.41849,
 'heldPercentInstitutions': 0.03232,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1442448000,
 'lastSplitFactor': '1:10',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/akaritx.com',
 'longBusinessSummary': 'Akari Therapeutics, Plc, a clinical-stage '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of treatments for a range of '
                        'rare and orphan autoimmune and inflammatory diseases. '
                        'Its lead product candidate is Coversin, a '
                        'second-generation complement inhibitor that is in '
                        'Phase II clinical trial for the treatment of '
                        'autoimmune and inflammatory diseases, including '
                        'paroxysmal nocturnal hemoglobinuria, guillain barr√© '
                        'syndrome, and atypical hemolytic uremic syndrome. '
                        'Akari Therapeutics, Plc is based in London, the '
                        'United Kingdom.',
 'longName': 'Akari Therapeutics, Plc',
 'market': 'us_market',
 'marketCap': 65243296,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_306632341',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -17945570,
 'nextFiscalYearEnd': 1640908800,
 'open': 2,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 20 8004 0270',
 'previousClose': 2,
 'priceHint': 4,
 'priceToBook': 30.952381,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2,
 'regularMarketDayLow': 1.94,
 'regularMarketOpen': 2,
 'regularMarketPreviousClose': 2,
 'regularMarketPrice': 2,
 'regularMarketVolume': 109151,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 33458100,
 'sharesPercentSharesOut': 0.0029,
 'sharesShort': 190907,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 66723,
 'shortName': 'Akari Therapeutics Plc',
 'shortPercentOfFloat': None,
 'shortRatio': 0.18,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'AKTX',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.927,
 'twoHundredDayAverage': 1.8544245,
 'volume': 109151,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.akaritx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'W1G 9RT'}